Should I buy or sell Aileron Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALRN shares. View ALRN analyst ratings or view top-rated stocks .

What is Aileron Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12-month target prices for Aileron Therapeutics' shares. Their ALRN share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 111.8% from the stock's current price. View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts .

How have ALRN shares performed in 2024?

Aileron Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, ALRN stock has increased by 39.3% and is now trading at $4.25. View the best growth stocks for 2024 here .

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 35,300 shares, an increase of 7.0% from the March 15th total of 33,000 shares. Based on an average daily volume of 39,200 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the company's stock are short sold. View Aileron Therapeutics' Short Interest .

When is Aileron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ALRN earnings forecast .

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings results on Friday, November, 12th. The company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40).

When did Aileron Therapeutics' stock split?

Shares of Aileron Therapeutics reverse split on the morning of Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA) , Acasti Pharma (ACST) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Allena Pharmaceuticals (ALNA) , OPKO Health (OPK) , Amarin (AMRN) , Aldeyra Therapeutics (ALDX) , Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV) .

When did Aileron Therapeutics IPO?

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

→ Start loving Mondays like this (From DTI) (Ad)

Free ALRN Stock Alerts

$4.25

-1.10 (-20.56%)

(As of 04/17/2024 ET)

Compare

Today's Range: $4.12
▼
$5.27
50-Day Range: $4.25
▼
$7.09
52-Week Range: $1.01
▼
$7.12

Volume: 65,936 shs
Average Volume: 40,278 shs
Market Capitalization: $20.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Aileron Therapeutics alerts:

Aileron Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 111.8% Upside
$9.00 Price Target
Short Interest: Healthy
0.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.17
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.97 out of 5 stars

Medical Sector

560th out of 912 stocks

Pharmaceutical Preparations Industry

248th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Aileron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aileron Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.88% of the float of Aileron Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aileron Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aileron Therapeutics has recently increased by 6.97%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aileron Therapeutics does not currently pay a dividend.
Dividend Growth
Aileron Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALRN.

2.9

News and Social Media Coverage

News Sentiment
Aileron Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Aileron Therapeutics this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for ALRN on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.57% of the stock of Aileron Therapeutics is held by insiders.
Percentage Held by Institutions
90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aileron Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aileron Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aileron Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

ALRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALRN Stock News Headlines

April 16, 2024 | investorplace.com

ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023

April 16, 2024 | finanznachrichten.de

Aileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 16, 2024 | americanbankingnews.com

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

April 15, 2024 | globenewswire.com

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 12, 2024 | markets.businessinsider.com

Aileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor Replacement

March 12, 2024 | globenewswire.com

Aileron Therapeutics Announces CEO Transition

February 15, 2024 | finance.yahoo.com

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

February 15, 2024 | globenewswire.com

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

February 1, 2024 | finance.yahoo.com

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

January 30, 2024 | msn.com

Aileron Therapeutics Announces Director Nomination Details

January 30, 2024 | msn.com

Aileron Therapeutics Announces 2024 Annual Meeting Plans

December 27, 2023 | benzinga.com

Aileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and Dates

December 15, 2023 | msn.com

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%

December 1, 2023 | realmoney.thestreet.com

Aileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics deal

December 1, 2023 | realmoney.thestreet.com

Aileron Therapeutics upgraded to Buy from Neutral at Ladenburg

November 5, 2023 | benzinga.com

Aileron Therapeutics Director Awarded $6K Worth of Stock Options

November 1, 2023 | msn.com

Aileron gains after all-stock deal to acquire Lung Therapeutics

October 31, 2023 | finance.yahoo.com

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

April 4, 2023 | finance.yahoo.com

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

March 22, 2023 | finance.yahoo.com

Aileron Therapeutics, Inc. (ALRN)

March 14, 2023 | finance.yahoo.com

Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

March 3, 2023 | msn.com

Looking Into Aileron Therapeutics's Recent Short Interest

February 23, 2023 | markets.businessinsider.com

JonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)

February 22, 2023 | finance.yahoo.com

Cancer drugmaker down to 3 employees after trial failure

February 21, 2023 | msn.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%

See More Headlines

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALRN
CUSIP: N/A
CIK: 1420565
Web: www.aileronrx.com
Phone: (617) 995-0900
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $9.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +111.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -83.80%
Return on Assets: -72.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.88
Quick Ratio: 7.88

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.10 per share
Price / Book: 1.04

Miscellaneous

Outstanding Shares: 4,890,000
Free Float: 4,613,000
Market Cap: $20.78 million
Optionable: Not Optionable
Beta: 2.22

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. James Brian Windsor Ph.D. (Age 57)
CEO & Director
Comp: $511.55k
Ms. Susan L. Drexler CPA (Age 54)
M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALRN shares.
View ALRN analyst ratings or view top-rated stocks.
What is Aileron Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12-month target prices for Aileron Therapeutics' shares. Their ALRN share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 111.8% from the stock's current price.
View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts.
How have ALRN shares performed in 2024?: Aileron Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, ALRN stock has increased by 39.3% and is now trading at $4.25.
View the best growth stocks for 2024 here.
Are investors shorting Aileron Therapeutics?: Aileron Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 35,300 shares, an increase of 7.0% from the March 15th total of 33,000 shares. Based on an average daily volume of 39,200 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the company's stock are short sold.
View Aileron Therapeutics' Short Interest.
When is Aileron Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ALRN earnings forecast.
How were Aileron Therapeutics' earnings last quarter?: Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings results on Friday, November, 12th. The company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40).

When did Aileron Therapeutics' stock split?: Shares of Aileron Therapeutics reverse split on the morning of Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Aileron Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).
When did Aileron Therapeutics IPO?: Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
How do I buy shares of Aileron Therapeutics?: Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALRN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial